

FMB

---

# NCI FACT BOOK

---

1981

National  
Cancer  
Program

U.S. DEPARTMENT  
OF HEALTH AND  
HUMAN SERVICES

Public Health  
Service

National  
Institutes of  
Health

---

# NCI FACT BOOK

---

National Cancer Program  
1981

NIH Publication No. 82-512  
April 1982

U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service      National Institutes of Health

## **PREFACE**

The information set forth in this publication is compiled and amended annually by the Financial Management Staff of the National Cancer Institute and is intended primarily for use by members of the Institute staff, the principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Manager, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland 20205.

# TABLE OF CONTENTS

	PAGE
Preface .....	ii
<b>GENERAL INFORMATION</b>	
Directory of Personnel .....	iv
Historical Data: Legislative Highlights .....	1
Historical Events .....	2
Director, NCP/NCI—President's Cancer Panel .....	3
National Cancer Advisory Board .....	4
Organizational Tables: National Cancer Institute .....	5
Office of the Director .....	6
Division of Cancer Biology and Diagnosis .....	7
Division of Cancer Cause and Prevention .....	8
Division of Cancer Treatment .....	10
Division of Resources, Centers, and Community Activities .....	12
Division of Extramural Activities .....	13
Total National Resources for Cancer Research and Cancer Control—Fiscal Year 1981 .....	14
Statistical Tables: Number of Deaths for the Five Leading Cancer Sites—1978 .....	15
Relationship of Cancer to Leading Causes of Death in the United States—1978 .....	15
Estimated Cancer Deaths and New Cases by Sex and Site—1981 .....	16
Research Positions at the National Cancer Institute .....	17
Building Location and Square Footage .....	19
<b>BUDGET DATA</b>	
NCI Budget Review Process .....	20
NCI Extramural Funds—Fiscal Year 1981 .....	21
National Cancer Institute Budget History by Mechanisms .....	22
NCI Research Programs—Fiscal Year 1981 .....	24
Total NCI Dollars by Mechanisms—Fiscal Year 1981 .....	25
NCI Program Structure—Fiscal Year 1981 .....	26
Cancer Control Obligations—Fiscal Years 1974-1981 .....	27
Reimbursement to NIH Management Fund—Fiscal Year 1981 .....	28
<b>GRANTS AND CONTRACTS</b>	
NCI Grant Process .....	29
NCI Contract Award Process .....	30
State Distribution of Grants and Contracts—Fiscal Year 1981 .....	31
Distribution of Cancer Control Grants and Contracts—Fiscal Year 1981 .....	32
Institutions Receiving More Than \$2,000,000 from the NCI—Fiscal Year 1981 .....	33
Distribution of NCI Contracts—Fiscal Year 1981 .....	35
Distribution of NCI Research Grants by Value of Grant Award—Fiscal Year 1981 .....	36
Distribution of the Grant Dollar—Fiscal Year 1981 .....	37
Foreign Research Grants and Contracts—Fiscal Year 1981 .....	38
<b>HISTORY TABLES</b>	
Appropriations of the NCI 1938-1982 .....	39
Comparison of Dollars, Positions and Space—1971-1981 .....	40
NCI Obligations and Outlays .....	41
NCI Grant Awards—1972-1981 .....	42
NCI Total Research Projects—1976-1981 .....	43

# DIRECTORY OF PERSONNEL

NATIONAL CANCER INSTITUTE  
NATIONAL INSTITUTES OF HEALTH  
BETHESDA, MARYLAND 20014

NIH Operator  
496-4000  
Area Code 301

		<b>DIRECT-IN DIALING</b>
<b>DIRECTOR</b>	<b>BUILDING 31</b>	
Dr. Vincent T. DeVita, Jr. ....	11-A-52 .....	496-5615
<b>DEPUTY DIRECTOR</b>	<b>BUILDING 31</b>	
Dr. Jane Henney .....	11-A-52 .....	496-3505
<b>ASSISTANT DIRECTOR</b>	<b>BUILDING 31</b>	
Dr. Bayard H. Morrison III .....	10-A-49 .....	496-3308
<b>ASSISTANT DIRECTOR</b>	<b>BUILDING 31</b>	
Dr. Elliott Stonehill .....	11-A-35 .....	496-1148
<b>ASSOCIATE DIRECTOR</b>	<b>BUILDING 31</b>	
Dr. Peter Fischinger .....	11-A-46 .....	496-1927
<b>ASSOCIATE DIRECTOR FOR PROGRAM PLANNING AND ANALYSIS</b>	<b>BUILDING 31</b>	
Mr. Louis M. Carrese .....	10-A-52 .....	496-6445
<b>CHIEF, PROGRAM ANALYSIS AND FORMULATION BRANCH</b>	<b>BUILDING 31</b>	
Dr. Michael Klein, Acting .....	10-A-52 .....	496-6445
<b>CHIEF, SYSTEMS PLANNING BRANCH</b>	<b>BUILDING 31</b>	
Ms. Barbara Murray, Acting .....	10-A-49 .....	496-5515
<b>ASSOCIATE DIRECTOR FOR CANCER COMMUNICATIONS</b>	<b>BUILDING 31</b>	
Mr. J. Paul Van Nevel .....	10-A-29 .....	496-6631
<b>CHIEF, INFORMATION RESOURCES BRANCH</b>	<b>BUILDING 31</b>	
Mr. Joseph Bangiolo .....	10-A-18 .....	496-6756
<b>CHIEF, REPORTS AND INQUIRIES BRANCH</b>	<b>BUILDING 31</b>	
Dr. Robert M. Hadsell .....	10-A-29 .....	496-6631
<b>CHIEF, INFORMATION PROJECTS BRANCH</b>	<b>BUILDING 31</b>	
Mr. Robert Denniston .....	4-B-39 .....	496-6793
<b>ASSOCIATE DIRECTOR FOR INTERNATIONAL AFFAIRS</b>	<b>BUILDING 31</b>	
Dr. Gregory T. O'Connor .....	11-A-19 .....	496-4761
<b>ASSOCIATE DIRECTOR FOR ADMINISTRATIVE MANAGEMENT</b>	<b>BUILDING 31</b>	
Mr. Philip Amoruso, Executive Officer .....	11-A-49 .....	496-5737
Mr. Robert M. Namovicz, Deputy Executive Officer .....	11-A-49 .....	496-5737
<b>CHIEF, ADMINISTRATIVE SERVICES BRANCH</b>	<b>BUILDING 31</b>	
Mr. James Prather .....	11-A-29 .....	496-5801
<b>CHIEF, FINANCIAL MANAGEMENT BRANCH</b>	<b>BUILDING 31</b>	
Mr. John P. Hartinger .....	11-A-18 .....	496-5803
<b>CHIEF, PERSONNEL MANAGEMENT BRANCH</b>	<b>BUILDING 31</b>	
Ms. Marianne Wagner .....	3-A-19 .....	496-3337
<b>CHIEF, RESEARCH CONTRACTS BRANCH</b>	<b>BLAIR BUILDING</b>	
Mr. James E. Graalman .....	316 .....	427-8810
<b>CHIEF, MANAGEMENT POLICY BRANCH</b>	<b>BUILDING 31</b>	
Mr. Thomas L. Kearns .....	4-A-51 .....	496-6985
<b>CHIEF, GRANTS ADMINISTRATION BRANCH</b>	<b>WESTWOOD BUILDING</b>	
Mr. Leo F. Buscher, Jr. ....	8-A-18 .....	496-7753
<b>CHIEF, GRANTS FINANCIAL DATA AND ANALYSIS BRANCH</b>	<b>WESTWOOD BUILDING</b>	
Mr. Robert E. Spallone .....	8-A-03 .....	496-7660

**DIRECT-IN  
DIALING**

**FREDERICK CANCER RESEARCH CENTER** **FREDERICK, MARYLAND**  
**GENERAL MANAGER/PROJECT OFFICER** **BUILDING**  
 Dr. Berge Hampar ..... 427 ..... FTS-8-935-7305

**ADMINISTRATIVE OFFICER** **BUILDING**  
 Mr. Richard Carter ..... 427 ..... FTS-8-935-2021

**DIRECTOR, DIVISION OF CANCER CAUSE AND PREVENTION** **BUILDING 31**  
 Dr. Richard Adamson ..... 11-A-03 ..... 496-6618

**ADMINISTRATIVE OFFICER** **BUILDING 31**  
 Mr. Stephen Ficca ..... 11-A-11 ..... 496-6556

**DIRECTOR, DIVISION OF CANCER BIOLOGY AND DIAGNOSIS** **BUILDING 31**  
 Dr. Alan S. Rabson ..... 3-A-03 ..... 496-4345

**ADMINISTRATIVE OFFICER** **BUILDING 31**  
 Mr. Larry D. Willhite ..... 3-A-05 ..... 496-3381

**DIRECTOR, DIVISION OF CANCER TREATMENT** **BUILDING 31**  
 Dr. Bruce Chabner, Acting ..... 3-A-52 ..... 496-4291

**ADMINISTRATIVE OFFICER** **BUILDING 31**  
 Mr. Michael Goldrich ..... 3-A-50 ..... 496-2775

**DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES** **BUILDING 31**  
 Mrs. Barbara Bynum ..... 10-A-03 ..... 496-5147

**ADMINISTRATIVE OFFICER** **BUILDING 31**  
 Ms. Jean Stein ..... 10-A-10 ..... 496-5915

**DIRECTOR, DIVISION OF RESOURCES, CENTERS, AND COMMUNITY ACTIVITIES** **BUILDING 31**  
 Dr. Peter Greenwald ..... 4A-32 ..... 496-6616

**ADMINISTRATIVE OFFICER** **BUILDING 31**  
 Mr. Nicholas Olimpio ..... 4A-46 ..... 496-9606

---

---

# NATIONAL CANCER INSTITUTE HISTORICAL DATA

---

---

---

## LEGISLATIVE HIGHLIGHTS

---

---

**July 23, 1937**—The National Cancer Institute Act, introduced by Congressman Warren G. Magnuson, was passed by Congress. An appropriation of \$700,000 for each fiscal year was authorized.

**July 1, 1944**—The Public Health Service Act, Public Law 410, 78th Congress provided that “The National Cancer Institute shall be a division in the National Institutes of Health.” The act also revised and consolidated many revisions into a single law. The limit of \$700,000 annual appropriation was removed.

**January 22, 1971**—In his State of the Union Message, President Nixon announced that he would ask for the appropriation of an additional \$100 million to launch an intensive effort to control cancer, and that he would ask later for whatever additional funds could be effectively used.

**December 23, 1971**—The President signed P. L. 92-218, The National Cancer Act of 1971, providing increased authorities and responsibilities for the NCI Director; initiating a National Cancer Program; establishing a three-member President’s Cancer Panel and a 23-member National Cancer Advisory Board; establishing cancer control programs as necessary for cooperation with State and other health agencies, and providing for the collection, analysis, and dissemination of all data useful in the diagnosis, prevention, and treatment of cancer, including the establishment of an international cancer research data bank.

**July 23, 1974**—The National Cancer Act Amendments of 1974, P.L. 93-352, was signed. The Amendments: encourage the NCP to explore the role of nutrition in the treatment, rehabilitation, and causation of cancer; authorize the Director to include personnel needs in the budget estimate to OMB; remove the limit on the number of comprehensive cancer centers; increase the number of expert appointments to 100; and direct the NCI to provide and contract for a program to disseminate and interpret information respecting the cause, prevention, diagnosis and treatment of cancer.

**August 1, 1977**—The Biomedical Research Extension Act of 1977, P.L. 95-83, increased the number of expert appointments from 100 to 151.

**November 9, 1978**—The Biomedical Research and Training Amendments of 1978, P.L. 95-622, was signed into law, authorizing appropriations for fiscal years 1979 and 1980. The amendments redefined the National Cancer Program to highlight prevention activities; expanded the membership of the National Cancer Advisory Board to 29 members; added basic research to the cancer centers authority; authorized travel and moving expenses to and from duty station for experts; and emphasized education and information in all aspects of the National Cancer Program.

**December 17, 1980**—The Health Programs Extension Act of 1980, P.L. 96-538, was signed into law, authorizing expenditure of funds for fiscal years 1981 and 1982.

---

## HISTORICAL EVENTS

---

- August 5, 1937**—President Franklin D. Roosevelt signed the National Cancer Act.
- November 9, 1937**—The National Advisory Cancer Council held its first meeting
- January 13, 1938**—Dr. Carl Voegtlin was appointed the first Director of the Institute.
- October 31, 1940**—President Franklin D. Roosevelt dedicated Building 6.
- July 1, 1947**—NCI reorganized to provide for expanded program; intramural cancer research, cancer research grants, and cancer control activities.
- July 2, 1953**—NCI inaugurated a full-scale clinical research program in the new Clinical Center.
- April 1955**—The Cancer Chemotherapy National Service Center was established in the Institute to coordinate the first national, voluntary, cooperative cancer chemotherapy program.
- January 11, 1966**—NCI reorganized to coordinate related activities. The areas of three Scientific Directors were established: Etiology; Chemotherapy; and a group of discipline-oriented laboratories and branches referred to as General Laboratories and Clinics.
- April 27, 1970**—At the request of Senator Ralph W. Yarborough, Chairman of the Committee on Labor and Public Welfare, the Senate approved the establishment of the National Panel of Consultants on the Conquest of Cancer.
- October 18, 1971**—President Nixon converted the Army's former biological warfare facilities at Fort Detrick, Md., to research on the causes, treatment and prevention of cancer.
- December 23, 1971**—President Nixon signed P.L. 92-218, The National Cancer Act of 1971.
- June 22, 1972**—The Institute awarded a contract for the operation and maintenance of the Frederick Cancer Research Center at Fort Detrick, Maryland. This constituted the largest research contract ever awarded by a research component of the National Institutes of Health.
- June 30, 1972**—A U. S.-U.S.S.R. agreement on the exchange of drugs, visiting scientists, and information was signed.
- July 27, 1972**—A Bureau-level organization was established for the National Cancer Institute, giving the Institute and its components organizational status commensurate with the responsibilities bestowed on it by The National Cancer Act of 1971. Under the reorganization, the Institute was composed of the Office of the Director and four Divisions.
- September 10, 1974**—NCI established the Division of Cancer Control and Rehabilitation, which will plan, direct and coordinate an integrated program of activities regarding the widespread application of available and new methods for reducing the incidence, morbidity and mortality from cancer.
- July 1975**—The Division of Cancer Treatment was expanded to include the NCI Surgery and Radiation Oncology Branches and the extramural program of Cancer Cooperative Clinical Trials.
- May 15, 1978**—The first phase of an extensive NCI reorganization was announced. Day-by-day administrative and funding responsibility for extramural research programs was consolidated in each of the four research divisions. Responsibility for grant and contract review committees and for other committee management activities was transferred to the Division of Cancer Research Resources and Centers.
- July 18, 1979**—NCI and the National Naval Medical Center entered into an agreement to cooperate in a research program in cancer treatment at the Naval Medical facility.
- July 14, 1980**—The Division of Extramural Affairs replaced the Division of Cancer Research Resources and Centers. Also, the new Division of Resources, Centers and Community Activities replaced the Division of Cancer Control and Rehabilitation.
- March 4, 1981**—A Biological Response Modifiers Program (BRMP) was officially established at NCI.
- July 14, 1981**—The NCI component of the National Toxicology Program was officially transferred to the National Institute of Environmental Health Sciences.
- 
-



**DIRECTOR  
NATIONAL CANCER PROGRAM  
NATIONAL CANCER INSTITUTE**

**Vincent T. DeVita, Jr., M.D.**

January 1, 1980 TO PRESENT

Dr. Vincent T. DeVita, Jr., received his B.S. degree in 1957 from the College of William and Mary and in 1961 received his M.D. degree with distinction from the George Washington School of Medicine. He interned at the University of Michigan Medical Center and then completed a year of residency with the George Washington University medical service. Dr. DeVita joined NCI in 1963 as a clinical associate, and after completing a senior residency at the Yale-New Haven Medical Center in 1965-66, returned to NCI as a senior investigator in the Solid Tumor Service and, in 1971, became Chief of the Medicine Branch. He was

named Director of the Division of Cancer Treatment in 1974 and, in 1975, Clinical Director of the Institute. In January 1980 he was appointed Acting Director, National Cancer Institute, and in July 1980, Director. Dr. DeVita serves on the editorial boards of numerous medical journals, maintains memberships in many scientific societies, and was President of the American Society of Clinical Oncology (1977-78). For his outstanding research and medical leadership, he has received a number of honors and awards, including the 1972 Albert and Mary Lasker Medical Research Award, and the 1980 Griffuel Prize.

**PRESIDENT'S CANCER PANEL**

	EXPIRATION OF APPOINTMENT
Dr. Armand Hammer, <i>Chairman</i> , 1982 Occidental Petroleum Corporation Washington, D. C.	1984
Dr. Harold Amos Harvard Medical School Boston, Massachusetts	1983
Dr. Bernard Fisher University of Pittsburgh Pittsburgh, Pennsylvania	1982

# NATIONAL CANCER ADVISORY BOARD

## APPOINTEES

	EXPIRATION OF APPOINTMENT
Dr. Henry C. Pitot, <i>Chairman</i> University of Wisconsin Madison, Wisconsin	1982
Dr. Bruce N. Ames University of California Berkeley, California	1982
Dr. Harold Amos Harvard Medical School Boston, Massachusetts	1982
Dr. Maureen M. Henderson University of Washington Seattle, Washington	1984
Dr. Robert C. Hickey M.D. Anderson Hospital and Tumor Institute Houston, Texas	1986
Dr. Joseph Gale Katterhagen Tacoma General Hospital Tacoma, Washington	1986
Mrs. Rose Kushner Writer/Consumer Interest Kensington, Maryland	1986
Ann Landers Field Newspaper Syndicate Chicago, Illinois	1986
Dr. LaSalle D. Leffall Howard University Washington, D. C.	1986

## EX OFFICIO MEMBERS

Dr. John H. Moxley, III Assistant Secretary of Defense (Health Affairs) Washington, D. C.
Dr. George A. Keyworth Office of Science and Technology Policy Washington, D. C.
Mr. Walter C. Barber Environmental Protection Agency Washington, D. C.
Mr. Stuart M. Statler Consumer Product Safety Commission Washington, D. C.
Mr. Raymond J. Donovan Secretary of Labor Washington, D. C.
Dr. Donald L. Custis Veterans Administration Washington, D. C.

## ALTERNATES TO EX OFFICIO MEMBERS

Dr. F. Kash Mostofi Chevy Chase, Maryland
Dr. Denis J. Prager Office of Science and Technology Policy Washington, D. C.
Dr. John Todhunter Environmental Protection Agency Washington, D. C.
Dr. Peter W. Preuss Health Sciences Bethesda, Maryland
Dr. Victor Alexander Department of Labor Washington, D. C.

## EXPIRATION OF APPOINTMENT

Mrs. Vincent Lombardi Manalapan, Florida	1982
Dr. William E. Powers Harper Grace Hospital Detroit, Michigan	1986
Dr. Janet D. Rowley University of Chicago Chicago, Illinois	1984
Mr. Sheldon W. Samuels AFL-CIO Washington, D. C.	1984
Mr. Morris M. Schrier MCA, Inc. New York, New York	1984
Dr. Frederick Seitz The Rockefeller University New York, New York	1982
Dr. Irving J. Selikoff Mount Sinai School of Medicine New York, New York	1984
Dr. Philippe Shubik Green College Oxford, England	1982
Dr. Gerald N. Wogan Massachusetts Institute of Technology Cambridge, Massachusetts	1984


Dr. Arthur H. Hayes, Jr. Food and Drug Administration Rockville, Maryland
Dr. J. Donald Millar National Institute for Occupational Safety and Health Atlanta, Georgia
Dr. David P. Rall National Institute of Environmental Health Sciences Research Triangle Park, North Carolina
Mr. Richard Schweiker Secretary for Health and Human Services Washington, D. C.
Dr. Thomas E. Malone National Institutes of Health, PHS Bethesda, Maryland


Dr. Hollis Boren Veterans Administration Washington, D. C.
Dr. Allen Heim Food and Drug Administration Rockville, Maryland
Dr. Elliott S. Harris National Institute for Occupational Safety and Health Atlanta, Georgia


## EXECUTIVE SECRETARY

Mrs. Barbara S. Bynum National Cancer Institute, NIH Bethesda, Maryland
---

# NATIONAL CANCER INSTITUTE







**DIVISION OF CANCER CAUSE AND PREVENTION**  
 Dr. Richard Adamson, Director

**ADMINISTRATIVE MANAGEMENT BRANCH**  
 Mr. Stephen Ficca

**BOARD OF SCIENTIFIC COUNSELORS**  
 Dr. Peter N. Magee, Chairman

Plans and directs a national program of laboratory, field, and demographic research on the cause and natural history of cancer and means for preventing cancer through direct intramural research, research grants, and contracts; evaluates mechanisms of cancer induction by viruses and by environmental carcinogenic hazards; tests for carcinogenic potential of environmental agents; serves as the focal point for the Federal Government on the synthesis of clinical, epidemiological, and experimental data relating to cancer; and participates in the evaluation of and advises the Institute Director on program-related aspects of the other grant and cancer control activities as they relate to cancer cause and prevention.

**FIELD STUDIES AND STATISTICS PROGRAM**  
 Dr. Joseph F. Fraumeni, Jr.

Plans, directs, coordinates, and evaluates a program of epidemiologic, statistical, and mathematical research activities and statistical and automatic data-processing services for all NCI research programs.

**CARCINOGENESIS INTRAMURAL PROGRAM**  
 Vacant

Plans, implements, and administers the Institute's program of general laboratory research on cancer causation by chemical, physical, and biological (viral) factors, and on the pathogenesis and prevention of various cancers.

**CARCINOGENESIS EXTRAMURAL PROGRAM**  
 Dr. John A. Cooper (acting)

Develops, evaluates, and administers the Institute's program of research grant, contract, and similarly supported extramural activities in cancer causation and prevention; responsible for program management, including improved management methods and practices, as well as maintaining liaison for extramural activities with various organizations and scientists.

**BIOMETRY BRANCH**  
 Dr. Earl S. Pollack

**CLINICAL EPIDEMIOLOGY BRANCH**  
 Dr. Robert W. Miller

**ENVIRONMENTAL EPIDEMIOLOGY BRANCH**  
 Dr. Joseph F. Fraumeni, Jr.

**LABORATORY OF TUMOR VIRUS GENETICS**  
 Dr. Edward Scolnik

**LABORATORY OF CELLULAR AND MOLECULAR BIOLOGY**  
 Dr. Stuart Aaronson

**LABORATORY OF BIOLOGY**  
 Dr. Joseph DiPaolo

**LABORATORY OF MOLECULAR CARCINOGENESIS**

**LABORATORY OF VIRAL CARCINOGENESIS**  
 Dr. George Todaro

**LABORATORY OF CARCINOGEN METABOLISM**  
 Dr. Snorri Thorgeirsson

**LABORATORY OF EXPERIMENTAL PATHOLOGY**  
 Dr. Umberto Saffiotti

**LABORATORY OF MOLECULAR VIROLOGY**

**SPECIAL PROGRAMS BRANCH**  
 Dr. John A. Cooper (acting)

**BIOLOGICAL CARCINOGENESIS BRANCH**  
 Dr. James T. Duff

**CHEMICAL AND PHYSICAL CARCINOGENESIS BRANCH**  
 Dr. Thaddeus Domanski

ENVIRONMENTAL  
EPIDEMIOLOGY BRANCH  
Dr. Joseph F. Fraumeni, Jr.

LABORATORY OF BIOLOGY  
Dr. Joseph DiPaolo

LABORATORY OF  
EXPERIMENTAL PATHOLOGY  
Dr. Umberto Saffiotti

CHEMICAL AND PHYSICAL  
CARCINOGENESIS BRANCH  
Dr. Thaddeus Domanski

LABORATORY OF  
MOLECULAR CARCINOGENESIS  
Dr. Harry V. Gelboin

LABORATORY OF  
MOLECULAR VIROLOGY  
Dr. George Khoury

LABORATORY OF  
CHEMOPREVENTION  
Dr. Michael B. Sporn

LABORATORY OF  
MOLECULAR ONCOLOGY  
Dr. George Vande Woude

LABORATORY OF HUMAN  
CARCINOGENESIS  
Dr. Curt Harris

LABORATORY OF CELLULAR  
CARCINOGENESIS AND  
TUMOR PROMOTION  
Dr. Stuart Yuspa

LABORATORY OF  
COMPARATIVE  
CARCINOGENESIS  
Dr. Jerry Rice

**DIVISION OF CANCER TREATMENT**  
 Dr. Bruce Chabner, Acting Director

Plans, directs, and coordinates an integrated program of cancer treatment activities with the objective of curing or controlling cancer in man by utilizing combination modalities including chemical, surgical, radiological, nutrition, antiemetic research, and certain immunological techniques, through intramural laboratory and clinical studies, contract and grant research, and research conducted in cooperation with other Federal agencies; administers a total drug development program encompassing all phases from drug acquisition up to and including clinical trials; and serves as the national focal point for information and data on experimental and clinical studies related to cancer treatment and for the distribution of such information to appropriate scientists and physicians.

**BOARD OF SCIENTIFIC COUNSELORS**  
 Dr. Samuel Hellman, Chairman

**ADMINISTRATIVE MANAGEMENT AND PLANNING BRANCH**  
 Mr. Michael Goldrich

**SCIENTIFIC INFORMATION BRANCH**  
 Ms. Susan M. Hubbard

**RADIOTHERAPY DEVELOPMENT BRANCH**  
 Dr. David Pistenmaa

**DIAGNOSTIC IMAGING RESEARCH BRANCH**  
 Dr. David Pistenmaa (acting)

**LOW-LEVEL RADIATION EFFECTS BRANCH**  
 Dr. Oddvar Nygaard (acting)

**CLINICAL ONCOLOGY PROGRAM**  
 Dr. Samuel Broder (acting)

Plans, directs, coordinates, and evaluates patient care activities of the NCI and a program of basic, applied, and clinical research in cancer treatment.

**BALTIMORE CANCER RESEARCH PROGRAM**  
 Dr. Hillel Socluf (acting)

Plans, directs, coordinates, and evaluates a program of laboratory and clinical research carried on by the NCI Baltimore Cancer Research Center.

**BIOLOGICAL RESPONSE MODIFIERS PROGRAM**  
 Dr. Robert Oldham

Plans, directs and coordinates a total research effort, extramural and intramural, aimed toward the assessment of the efficacy of biological response modifiers (BRM) and their use in the treatment of cancer.

**CANCER THERAPY EVALUATION PROGRAM**  
 Dr. John S. MacDonald

Plans, evaluates, and coordinates extramural clinical research programs testing combined modality approaches and the testing of investigational new agents; and directs the evaluation of the effectiveness of specific types and methods of cancer therapy and analyzes and assesses the applicability of new methods and agents in the clinical treatment of cancer.

**DEVELOPMENTAL THERAPEUTICS PROGRAM**  
 Dr. John Driscoll (acting)

Plans, directs, and conducts a basic and applied research program in the preclinical development of therapeutic modalities, especially those related to chemotherapy; and through intramural laboratories and contracts, administers research in programmed preclinical evaluation of potential cancer therapeutic agents, molecular pharmacology and toxicology of drugs, and molecular biological aspects of neoplastic transformation.

**MEDICINE BRANCH**  
 Dr. Robert C. Young

**PEDIATRIC ONCOLOGY BRANCH**  
 Dr. Arthur S. Levine

**NCI-NAVY MEDICAL ONCOLOGY BRANCH**

**CLINICAL ONCOLOGY BRANCH**  
 Dr. Peter H. Wiernik

**LABORATORY OF MOLECULAR BIOLOGY**  
 Dr. Carl C. Levy

**LABORATORY OF CLINICAL BIOCHEMISTRY**

**BIOLOGICAL DEVELOPMENT BRANCH**  
 Dr. Robert Oldham (acting)

**BIOLOGICAL RESOURCES BRANCH**  
 Dr. W. John Martin

**INVESTIGATIONAL DRUG BRANCH**  
 Dr. Daniel Hoth

**BIOLOGICS EVALUATION BRANCH**  
 Dr. John S. MacDonald (acting)


**RADIOTHERAPY DEVELOPMENT BRANCH**  
 Dr. David A. Pistenmaa


**DRUG SYNTHESIS AND CHEMISTRY BRANCH**  
 Dr. Ven Narayanan

**EXTRAMURAL RESEARCH & RESOURCES BRANCH**  
 Dr. Moreshwar Nadkarni

**NATURAL PRODUCTS BRANCH**  
 Dr. John D. DeWors







**DIVISION OF EXTRAMURAL ACTIVITIES**

**Mrs. Barbara S. Bynum, Director**

Administers and directs the Institute's grant and contract review and processing activities; provides initial technical and scientific merit review of grants and contracts for the Institute; provides grants management for the Institute; represents the Institute on over-all NIH extramural and collaborative program policy committees, coordinates such policy within NCI, and develops and recommends NCI policies and procedures as related to the review of grants and contracts, coordinates the Institute's review of research grant and training programs with the National Cancer Advisory Board and the President's Cancer Panel; coordinates the implementation of committee management policies within the Institute and provides the Institute's staff support for the National Cancer Advisory Board and the President's Cancer Panel; coordinates program planning and evaluation in the extramural area; provides scientific reports and analyses to the Institute's grant and contract programs; provides financial data and analyses on grants and contracts to the Institute; and recommends to the Director, NCI, funding levels of extramural programs.

**CONTRACTS REVIEW  
BRANCH**

**Dr. David Joftes**

**GRANTS REVIEW  
BRANCH**


**Dr. Dennis Cain**

**RESEARCH ANALYSIS AND  
EVALUATION BRANCH**

**Mr. Harry Y. Canter**

# TOTAL NATIONAL RESOURCES FOR CANCER RESEARCH AND CANCER CONTROL—FISCAL YEAR 1981

TOTAL \$1,887,992,000



NOTE: Non-NCI resources data were provided by the Office of Program Planning and Analysis, NCI.

## NUMBER OF DEATHS FOR THE FIVE LEADING CANCER SITES BY AGE GROUP AND SEX—1978

TOTAL		UNDER 15		15-34		35-54		55-74		75+	
MALE	FEMALE	MALE	FEMALE	MALE	FEMALE	MALE	FEMALE	MALE	FEMALE	MALE	FEMALE
<b>Lung</b> 71,006	<b>Breast</b> 34,329	Leukemia 550	Leukemia 411	Leukemia 827	Breast 585	Lung 10,124	Breast 8,205	Lung 46,049	Breast 17,403	Lung 14,646	Colon & Rectum 12,626
<b>Colon &amp; Rectum</b> 25,696	<b>Colon &amp; Rectum</b> 27,573	Brain & CNS 344	Brain & CNS 275	Brain & CNS 467	Leukemia 493	Colon & Rectum 2,462	Lung 4,679	Colon & Rectum 13,717	Lung 14,463	Prostate 12,298	Breast 8,129
<b>Prostate</b> 21,674	<b>Lung</b> 24,080	Bone 47	Bone 45	Hodgkin's Disease 335	Brain & CNS 347	Pancreas 1,262	Colon & Rectum 2,210	Prostate 9,047	Colon & Rectum 12,551	Colon & Rectum 9,325	Lung 4,819
<b>Pancreas</b> 11,010	<b>Uterus</b> 10,842	Connective Tissue 43	Kidney 44	Testis 329	Uterus 295	Brain & CNS 1,282	Uterus 2,111	Pancreas 6,490	Ovary 5,992	Pancreas 3,208	Pancreas 3,939
<b>Stomach</b> 8,529	<b>Ovary</b> 10,651	Kidney 39	Connective Tissue 43	Melanoma of the skin 261	Hodgkin's Disease 223	Leukemia 1,065	Ovary 2,029	Stomach 4,558	Uterus 5,480	Bladder 3,172	Uterus 2,954

SOURCE: Vital Statistics of the United States, 1978.

## RELATIONSHIP OF CANCER TO LEADING CAUSES OF DEATH IN THE UNITED STATES—1978

RANK	CAUSE OF DEATH	NUMBER OF DEATHS	DEATH RATE PER 100,000 POPULATION	PERCENT OF TOTAL DEATHS
	<b>All Causes</b>	<b>1,927,788</b>	<b>883.4</b>	<b>100.0</b>
1	Diseases of Heart	729,510	334.3	37.8
2	<b>Cancer</b>	<b>396,992</b>	<b>181.9</b>	<b>20.6</b>
3	Stroke	175,629	80.5	9.1
4	Accidents	105,561	48.4	5.5
5	Influenza and Pneumonia	58,319	26.7	3.0
6	Diabetes Mellitus	33,841	15.5	1.8
7	Cirrhosis of Liver	30,066	13.8	1.6
8	Arteriosclerosis	28,940	13.3	1.5
9	Suicide	27,294	12.5	1.4
10	Diseases of Infancy	22,033	10.1	1.1
11	Bronchitis, Emphysema, and Asthma	21,875	10.0	1.1
12	Homicide	20,432	9.4	1.1
13	Congenital Anomalies	12,968	5.9	0.7
14	Nephritis and Nephrosis	8,868	4.1	0.5
15	Septicemia and Pyemia	7,800	3.6	0.4
	Other and Ill-Defined	24,766	113.5	12.8

SOURCE: National Center for Health Statistics, 1978.

# ESTIMATED CANCER DEATHS AND NEW CASES BY SEX AND SITE—1981<sup>1</sup>

SITE	ESTIMATED DEATHS			ESTIMATED NEW CASES		
	TOTAL	MALE	FEMALE	TOTAL	MALE	FEMALE
All Sites	420,000	227,500	192,500	815,000 <sup>1</sup>	403,000 <sup>1</sup>	412,000 <sup>1</sup>
Buccal Cavity & Pharynx (Oral)	9,150	6,300	2,850	26,600	18,400	8,200
Lip	175	150	25	4,600	4,100	500
Tongue	2,000	1,400	600	4,800	3,200	1,600
Salivary Gland	700	450	250	9,600	5,700	3,900
Floor of Mouth	525	400	125			
Other & Unspecified Mouth	1,550	1,000	550			
Pharynx	4,200	2,900	1,300	7,600	5,400	2,200
Digestive Organs	110,500	57,600	52,900	194,500	99,700	94,800
Esophagus	8,100	5,800	2,300	8,800	6,200	2,600
Stomach	13,900	8,400	5,500	23,900	14,500	9,400
Small Intestine	700	350	350	2,100	1,100	1,000
Large Intestine } (Colon- Rectum } Rectum)	46,200	21,500	24,700	83,000	38,000	45,000
Rectum	8,700	4,700	4,000	37,000	20,000	17,000
Liver & Biliary Passages	9,400	4,600	4,800	13,000	6,000	7,000
Pancreas	22,000	11,500	10,500	24,200	12,700	11,500
Other & Unspecified Digestive	1,500	750	750	2,500	1,200	1,300
Respiratory System	110,100	81,000	29,100	135,800	99,000	36,800
Larynx	3,700	3,100	600	10,700	9,000	1,700
Lung	105,000	77,000	28,000	122,000	88,000	34,000
Other & Unspecified Respiratory	1,400	900	500	3,100	2,000	1,100
Bone, Tissue & Skin	10,050	5,800	4,250	20,900	10,700	10,200
Bone	1,750	1,000	750	1,900	1,100	800
Connective Tissue	1,600	800	800	4,700	2,600	2,100
Skin	6,700 <sup>4</sup>	4,000	2,700	14,300 <sup>2</sup>	7,000 <sup>2</sup>	7,300 <sup>2</sup>
Breast	37,100	300	36,800	110,900	900	110,000
Genital Organs	46,400	23,700	22,700	151,600	75,200	76,400
Cervix, Invasive } Uterus	7,200	—	7,200	16,000 <sup>3</sup>	—	16,000 <sup>3</sup>
Corpus, Endometrium }	3,100	—	3,100	38,000	—	38,000
Ovary	11,400	—	11,400	18,000	—	18,000
Prostate	22,700	22,700	—	70,000	70,000	—
Other & Unspecified Genital, Male	1,000	1,000	—	5,200	5,200	—
Other & Unspecified Genital, Female	1,000	—	1,000	4,400	—	4,400
Urinary Organs	18,700	12,200	6,500	54,600	38,000	16,600
Bladder	10,600	7,300	3,300	37,000	27,000	10,000
Kidney & Other Urinary	8,100	4,900	3,200	17,600	11,000	6,600
Eye	400	200	200	1,800	900	900
Brain & Central Nervous System	10,200	5,600	4,600	12,100	6,700	5,400
Endocrine Glands	1,500	600	900	10,800	3,300	7,500
Thyroid	1,050	350	700	9,900	2,800	7,100
Other Endocrine	450	250	200	900	500	400
Leukemia	15,900	8,900	7,000	23,400	13,000	10,400
Other Blood & Lymph Tissues	21,600	11,200	10,400	39,500	20,900	18,600
Hodgkin's Disease	1,700	1,000	700	7,100	4,100	3,000
Multiple Myeloma	6,700	3,400	3,300	9,400	4,800	4,600
Other Lymphomas	13,200	6,800	6,400	23,000	12,000	11,000
All Other & Unspecified Sites	28,400	14,100	14,300	32,500	16,300	16,200

Note: The estimates of new cancer cases are offered as a rough guide and should not be regarded as definitive. Especially note that year-to-year changes only represent improvements in the basic data.

<sup>1</sup> Carcinoma in situ and non-melanoma skin cancers not included in totals. Carcinoma in situ of the uterine cervix accounts for over 45,000 new cases annually. Non-melanoma skin cancer accounts for about 400,000 new cases annually. <sup>2</sup> Melanoma only <sup>3</sup> Invasive cancer only. <sup>4</sup> Melanoma 5,000; other skin 1,700.

Incidence estimates are based on rates from NCI SEER Program, 1973-1977.

# RESEARCH POSITIONS AT THE NATIONAL CANCER INSTITUTE<sup>1</sup>

The National Cancer Institute recognizes that one of the most valuable resources to be drawn upon in the fight against cancer is the wealth of scientific talent available in the U. S. and around the world. In an effort to attract and maintain the highest quality scientific staff, two personnel systems are used: the U. S. Civil Service System and the PHS Commissioned Corps. In addition, the Staff Fellowship Program and the NIH Visiting Program have been designed to meet special needs. Special programs are also available for those who qualify.

POSITION	ELIGIBILITY	ANNUAL SALARY	MECHANISM OF ENTRY
<b>I. CIVIL SERVICE</b>			
<b>A. Civil Service (tenured)</b>	Appropriate advanced education, experience and knowledge needed by NCI to conduct its programs.	Minimum starting: Ph.D. — \$33,086 Physicians — \$42,546 Maximum: \$57,500	Office of Personnel Management, Contact Director or Laboratory Chief in area of interest or the NCI Personnel Office.
<b>II. SPECIAL APPOINTMENT OF EXPERTS AND CONSULTANTS</b>			
<b>A. Special Appointment of Experts and Consultants (non-tenured appointment which can be extended up to 4 years.)</b>	Applicants shall possess outstanding experience and ability as to justify recognition as authorities in their particular fields of activity.	Equivalent to the salary range of GS-13 through GS-18.  Maximum: \$57,500	Recommendation by Division Directors. Final approval rests with the Director, NCI.
<b>III. MEDICAL STAFF FELLOWS</b>			
<b>A. Medical Staff Fellows</b>	Appointment for 2 or 3 years with an additional 1-year extension for an initial 2-year appointment. Graduate of accredited medical or osteopathic school and completion of internship. Completion of 2 or 3 years of clinical training beyond the M.D. degree and demonstrated outstanding ability to conduct successfully, preestablished programs in both clinical and laboratory research.	\$30,000-\$34,000	Apply to the Clinical and Professional Education Section, Clinical Center, National Institutes of Health 20205.
<b>B. Medical Staff Fellows in Pharmacology (PRAT Fellows). For physicians committed to research careers in pharmacological sciences, or clinical pharmacology.</b>	Appointment for 2 or 3 years with an additional 1-year extension for an initial 2-year appointment. Graduate of accredited medical or osteopathic school and completion of internship. Completion of 2 or 3 years of clinical training beyond the M.D. degree and demonstrated outstanding ability to conduct successfully, preestablished programs in both clinical and laboratory research.	\$30,000-\$34,000	Apply to the Clinical and Professional Education Section, Clinical Center, National Institutes of Health 20205.
<b>IV. VISITING PROGRAM (limited tenure)<sup>2</sup></b>			
<b>A. Visiting Fellow (maximum 3 years)</b>	1-3 years postdoctoral experience or training.	Entrance stipend \$16,000-\$17,000  No dependency allowance provided.	Contact Director or Laboratory Chief in area of interest.
<b>B. Visiting Associates (1 year with renewals to end of project)</b>	3+ years postdoctoral experience or training with appropriate knowledge needed by NCI.	\$19,477-\$36,723	Contact Director or Laboratory Chief in area of interest.
<b>C. Visiting Scientist (duration of project)</b>	6+ years postdoctoral experience with appropriate unusual experience and knowledge needed.	\$28,245-\$57,500	Contact Director or Laboratory Chief in area of interest.

## V. STAFF FELLOWSHIPS

POSITION	ELIGIBILITY	ANNUAL SALARY	MECHANISM OF ENTRY
A. Staff Fellowship	Physician or other doctoral degree equivalent awarded within last 5 years, U.S. citizen or non-citizen eligible for naturalization within 4 years.  Maximum five-year appointment.	Staff Fellows Physicians \$20,688-\$32,998 Other Doctorates \$17,000-\$32,955 Senior Staff Fellows Physicians \$23,439-\$44,786 Other Doctorates \$20,688-\$36,946	Contact Director or Laboratory Chief in area of interest or the NCI Personnel Office.

## VI. CIVIL SERVICE SUMMER EMPLOYMENT PROGRAMS

A. Summer Clerical Program	Must be 18 years of age or older (16 if high school graduate).	GS-1 through GS-4 Grade is based on education and/or experience.	Apply to NIH on or before March 15.
B. Summer Undergraduate Program	Students majoring in biological and/or physical sciences or related field, or applicants with appropriate experience.	GS-1 through GS-4 Grade is based on education and/or experience.	Apply to NIH by March 15. No written test is required.
C. Summer Graduate Program	College graduate, graduate student, planning to attend graduate school, faculty member, or equivalent experience and/or education.	GS-5 through GS-12 For some occupations superior scholastic work may qualify for a higher grade level.	Apply to NIH by March 15.
D. Summer Employment for Needy Youth	Educationally and economically disadvantaged youths in their formative years (must have reached 16th birthday).	Federal minimum wage.	Register with the local office of the State Employment service and apply to NIH.
E. Stay-in-School Program	Substantially full-time or full-time student at least 16 years of age who needs earnings from employment to continue in school.	Salary is commensurate with duties assigned and student's education and/or experience.	Apply to NIH. No deadline required for applying. However, no new appointments are made between May 1 to August 30.
F. The Federal Junior Fellowship Program	Graduating high school senior in a public or private school in the Metro. Wash., D. C. area. Must be in upper 10% of graduating class, have applied for admission to an accredited college or university and need financial assistance to attend school.	GS-1 through GS-4	Nominations are submitted directly to the Office of Personnel Management by high school principals or counselors.


## VII. SPECIAL PROGRAMS

A. Research Fellow sponsored by organization other than NIH, PHS.	Determined by sponsoring organization.	Established by sponsoring organization.	Contact Director or Laboratory Chief in area of interest; also apply to sponsoring agency, e.g., American Cancer Society, Eleanor Roosevelt Cancer Foundation, Leukemia Society of America, Inc., etc.
B. COSTEP Program (operates year-round) Maximum 120 days per 12-month period.	U.S. Citizen. Must have completed one year of study in a medical, dental or veterinary school; or a minimum of two years of baccalaureate program in a health-related field such as engineering, nursing, pharmacy, etc. May be enrolled in a master's or doctoral program in a health-related field (designated by the Assistant Secretary for Health). Physical requirements of PHS Commissioned Corps. Plans to return to college.	Pay and allowance of a Commissioned Officer, Junior Asst. Grade.	Apply to PHS Commissioned Corps, COSTEP SECTION, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20852.
C. Fogarty International Scholars	International reputation, productivity, demonstrated ability in biomedical field.	\$42,000 per annum	Recommendation to Fogarty Center by Institute Director or Scientist. Contact Director in area of interest.

<sup>1</sup> Does not necessarily indicate that positions are currently available at the National Cancer Institute.

<sup>2</sup> Under most circumstances, the various visiting programs are limited to non-citizens.





**BUILDING 10  
CLINICAL CENTER**  
82,101 Square Feet  
370 Personnel

**BUILDING 37**  
117,249 Square Feet  
416 Personnel

**BUILDING 13**  
584 Square Feet  
3 Personnel

**BUILDING 14**  
6,056 Square Feet  
4 Personnel

**BUILDING 31**  
37,384 Square Feet  
209 Personnel

**BUILDING 8**  
12,747 Square Feet  
36 Personnel

**BUILDING 41**  
31,353 Square Feet  
78 Personnel

**LANDOW BUILDING**  
55,419 Square Feet  
280 Personnel

**BUILDING LOCATION AND  
SQUARE FOOTAGE OCCUPIED  
BY FULL-TIME PERMANENT  
PERSONNEL IN BETHESDA,  
MARYLAND AREA  
AS OF SEPTEMBER 30, 1981**


**TOTAL\***  
Approximately 472,633 Square Feet  
1,815 Personnel

**\*INCLUDED BUT  
NOT SHOWN**  
**FIELD STATIONS**  
48,925 Square Feet  
98 Personnel

**BLAIR BUILDING**  
8300 Colesville Road  
Silver Spring, MD  
20910  
49,953 Square Feet  
197 Personnel

**WESTWOOD BUILDING**  
30,862 Square Feet  
124 Personnel

# NCI BUDGET REVIEW PROCESS




KEY:  INSTITUTE FUNCTION  DIVISION FUNCTION

FY 1 = FIRST FUTURE FISCAL YEAR    FY 2 = SECOND FUTURE FISCAL YEAR

NOTE: Contracts include Cooperative Agreements and Interagency Agreements.

# NCI EXTRAMURAL FUNDS — FISCAL YEAR 1981

**Total Extramural**  
\$783,466,000



**Total Intramural (not shown)** \$205,872,000  
**Total NCI** \$989,338,000


# NATIONAL CANCER INSTITUTE BUDGET HISTORY BY MECHANISMS

(DOLLARS IN THOUSANDS)

	1972 ACTUAL		1973 ACTUAL		1974 ACTUAL		1975 ACTUAL	
	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL
<b>Group I – Investigator Initiated</b>								
Regular Research Grants	\$ 59,207	18.9	\$ 73,412	21.1	\$ 99,415	21.5	\$115,195	21.4
Clinical Cooperative Groups	10,102	3.2	12,791	3.7	16,196	3.5	19,213	3.6
Program Projects – PO1's	38,415	12.2	52,008	14.9	71,997	15.6	84,536	15.7
Clinical Education Program	–	–	–	–	–	–	5,033	.9
Research Career Program	2,026	.7	1,818	.5	1,673	.4	2,806	.5
Fellowships and Training	18,395	5.9	13,888	4.0	23,562	5.1	23,104	4.3
Organ Site	638	.2	3,950	1.1	10,007	2.2	11,167	2.1
Cancer Centers – Core Support	10,090	3.2	13,002	3.7	17,575	3.8	30,096	5.6
Cooperative Agreements	–	–	–	–	–	–	–	–
Minority Biomedical Support	–	–	–	–	–	–	–	–
Subtotal	138,873	44.3	170,869	49.0	240,525	52.1	291,150	54.1
<b>Group II – Co-Initiated</b>								
CREG/RFA	–	–	–	–	–	–	–	–
Research Contracts	46,802	14.9	61,187	17.6	94,964	20.5	105,076	19.5
Subtotal	46,802	14.9	61,187	17.6	94,964	20.5	105,076	19.5
<b>Group III – NCI/NCP Initiated</b>								
Resource Contracts	63,194	20.2	64,838	18.6	72,365	15.7	82,916	15.4
Interagency Agreements	12,053	3.8	10,136	2.9	13,031	2.8	11,593	2.2
Subtotal	75,247	24.0	74,974	21.5	85,396	18.5	94,509	17.6
<b>Group IV – Other Resources</b>								
Planning Grants	1,698	.5	2,500	.7	2,880	.6	2,568	.4
Construction Grants	47,004	15.0	34,737	10.0	31,692	6.9	30,000	5.6
Construction Contracts	3,999	1.3	4,067	1.2	6,398	1.4	14,976	2.8
Subtotal	52,701	16.8	41,304	11.9	40,970	8.9	47,544	8.8
Total	313,623	100.0	348,334	100.0	461,755	100.0	538,279	100.0
Percent of Total NCI Budget		84.2		81.9		79.5		77.0
In-House Research	25,696	6.9	33,032	7.8	40,364	6.9	50,532	7.2
Management & Support	33,246	8.9	39,072	9.2	46,169	7.9	61,935	8.9
(NIH Management Fund)	(12,910)	(3.5)	(15,194)	(3.6)	(16,754)	(2.9)	(20,248)	(2.9)
Cancer Control (Grants & Contracts)	–	–	4,969	1.1	32,826	5.7	48,574	6.9
Subtotal	58,942	15.8	77,073	18.1	119,359	20.5	161,041	23.0
<b>Total NCI</b>	<b>\$372,565</b>	<b>100.0</b>	<b>\$425,407</b>	<b>100.0</b>	<b>\$581,114</b>	<b>100.0</b>	<b>\$699,320</b>	<b>100.0</b>

1976 ACTUAL		1977 ACTUAL		1978 ACTUAL		1979 ACTUAL		1980 ACTUAL		1981 ACTUAL	
DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL
\$130,633	22.7	\$140,159	23.0	\$158,716	24.7	\$188,488	27.3	\$213,610	29.0	\$237,662	32.6
23,263	4.0	27,121	4.5	29,774	4.6	32,021	4.6	36,884	5.0	35,094	4.8
80,029	13.9	83,453	13.7	88,058	13.7	93,953	13.6	104,094	14.1	115,311	15.8
7,698	1.3	8,996	1.5	9,952	1.5	11,404	1.7	10,906	1.5	7,999	1.1
3,243	.6	3,507	.6	4,339	.7	4,771	0.7	5,357	0.7	5,480	0.8
18,160	3.1	19,791	3.3	20,129	3.1	20,139	2.9	27,260	3.7	25,606	3.5
14,090	2.5	14,711	2.4	16,194	2.5	17,032	2.5	17,554	2.4	15,962	2.2
47,803	8.3	55,132	9.1	60,348	9.4	64,364	9.3	67,421	9.1	71,408	9.8
-	-	-	-	-	-	-	-	800	0.1	300	-
-	-	-	-	-	-	-	-	1,980	0.3	1,727	0.2
324,919	56.4	352,870	58.1	387,570	60.2	432,172	62.6	485,866	65.9	516,549	70.8
2,577	.5	7,266	1.2	9,412	1.5	7,894	1.1	6,971	0.9	6,712	0.9
111,524	19.3	110,740	18.6	120,359	18.6	81,119	11.8	57,446	7.8	43,928	6.0
114,101	19.8	118,006	19.4	129,771	20.1	89,013	12.9	64,417	8.7	50,640	6.9
96,509	16.7	94,229	15.5	87,806	13.6	130,161	18.9	151,305	20.5	140,622	19.3
13,262	2.3	19,414	3.2	21,621	3.4	20,734	3.0	20,615	2.8	16,881	2.3
109,771	19.0	113,643	18.7	109,427	17.0	150,895	21.9	171,920	23.3	157,503	21.6
2,803	.5	1,199	.2	632	.1	271	.1	221	-	-	-
20,000	3.5	16,000	2.6	12,000	1.9	12,452	1.8	10,814	1.5	2,027	.3
4,721	.8	5,992	1.0	4,544	.7	4,878	.7	4,618	.6	3,200	.4
27,524	4.8	39,191	3.8	17,176	2.7	17,601	2.6	15,653	2.1	5,227	.7
576,315	100.0	607,710	100.0	643,944	100.0	689,681	100.0	737,856	100.0	729,919	100.0
	75.7		74.6		73.8		73.6		73.9		73.8
61,243	8.0	67,855	8.3	79,217	9.1	88,944	9.5	98,665	9.9	109,377	11.0
69,876	9.2	80,184	9.8	86,594	9.9	91,167	9.7	97,863	9.8	96,495	9.8
(23,037)	(3.0)	(26,817)	(3.3)	(30,150)	(3.5)	(35,622)	(3.8)	(39,549)	(4.0)	(42,471)	(4.3)
54,016	7.1	59,208	7.3	62,614	7.2	66,904	7.2	63,663	6.4	53,547	5.4
185,135	24.3	207,247	25.4	228,425	26.2	247,015	26.4	260,191	26.1	259,419	26.2
<b>\$761,450</b>	<b>100.0</b>	<b>\$814,957</b>	<b>100.0</b>	<b>\$872,369</b>	<b>100.0</b>	<b>\$936,696</b>	<b>100.0</b>	<b>\$998,047</b>	<b>100.0</b>	<b>\$989,338</b>	<b>100.0</b>

# NCI RESEARCH PROGRAMS — FISCAL YEAR 1981



Research Programs	Dollars	PERCENT OF TOTAL
Research Programs	\$814,730,000	82.4
Resource Development		
Cancer Centers Support	72,965,000	7.4
Research Manpower Development	40,108,000	4.0
Construction	6,103,000	0.6
Cancer Control	55,432,000	5.6
<b>Total NCI</b>	<b>\$989,338,000</b>	<b>100.0</b>


# TOTAL NCI DOLLARS BY MECHANISMS — FISCAL YEAR 1981

(DOLLARS IN THOUSANDS)

	AMOUNT	MECHANISM	PERCENT OF TOTAL	
	<b>RESEARCH PROJECT GRANTS</b>			
\$355,455	\$229,103	Traditional (R01)	23.1	35.9%
	4,329	Young Investigators	0.4	
	6,712	Cancer Research Emphasis Grants/RFA's	0.7	
	115,311	Program Projects	11.7	
	<b>RESEARCH CENTERS GRANTS</b>			
\$71,408	579	Other Centers	.06	7.2%
	70,829	Center Core Grants	7.16	
	<b>OTHER RESEARCH GRANTS</b>			
\$70,506	3,013	Scientific Evaluation	0.3	7.1%
	1,217	Conference Grants	0.1	
	4,817	Research Career Programs	0.5	
	7,999	Clinical Education Programs	0.8	
	35,094	Clinical Cooperative Groups	3.5	
	15,962	National Organ Site Program	1.6	
	377	Veterinary Pathology Awards	.04	
	300	Cooperative Agreements	.03	
	1,727	Minority Biomedical Support	0.2	
	<b>TRAINING PROGRAM</b>			
\$25,606	4,046	National Research Service Awards—Individual	0.41	2.6%
	21,560	National Research Service Awards—Institutional	2.2	
	<b>RESEARCH AND RESOURCE CONTRACTS</b>			
\$201,431	201,431	Research and Resource Contracts	20.4	20.4%
	<b>CANCER CONTROL</b>			
\$56,165	56,165	Cancer Control	5.7	5.7%
	<b>CONSTRUCTION</b>			
\$5,227	5,227	Construction	0.5	0.5%
	<b>IN-HOUSE</b>			
\$203,540	155,484	Intramural Research	15.7	20.6%
	37,294	Direct Operations	3.8	
	10,762	Program Management	1.1	
	<b>\$989,338</b>	<b>TOTAL NCI</b>	<b>100.0</b>	


# NCI PROGRAM STRUCTURE — FISCAL YEAR 1981

**TOTAL DOLLARS**  
**\$989,338,000**






# CANCER CONTROL OBLIGATIONS BY MECHANISM — FISCAL YEARS 1974-1981



# REIMBURSEMENT TO NIH MANAGEMENT FUND — FISCAL YEAR 1981

**TOTAL NIH SERVICES**  
\$167,092,000



- CLINICAL CENTER**
- Employee Health Services
  - Service Functions
  - Social Work
  - Professional Services
  - Consultative Services
  - Admissions and Follow-up
  - Anesthesiology
  - Diagnostic X-Ray
  - Clinical Pathology
  - Blood Bank
  - Rehabilitation Service
  - Pharmacy Service
  - Medical Records
  - TV Engineering
  - Nursing Service
  - Patient Nutrition Service
  - Environmental Sanitation Control
  - Laundry
  - Radiation Safety

- STANDARD LEVEL USER CHARGES (SLUC)**
- Building usage including utilities
  - Major renovations
  - Guard services for rental buildings

\$17,841,000

\$1,606,000

**DISTRIBUTION OF NCI SERVICES**  
\$42,471,000



\$2,285,000

\$2,648,000

\$18,091,000

**DIVISION OF COMPUTER RESEARCH AND TECHNOLOGY**

Research & Development Program in Which Concepts & Methods of Computer Science Are Applied to Bio-medical Problems (In addition, services are rendered to the NIH Communities on a fee-for-service basis.)

**DIVISION OF RESEARCH GRANTS**


Initial Scientific Review of Applications  
Assignment of Research Grant Applications Among Institutes

**OTHER RESEARCH SERVICES**


Division of Administrative Services  
Division of Engineering Services  
Division of Safety  
Division of Research Services

The Management Fund provides for the financing of certain common research supporting services and administrative activities which are required in the operating of NIH.

# NCI GRANT PROCESS



# NCI CONTRACT AWARD PROCESS — UNDER CANCER ACT OF 1971



NOTE: SIMULTANEOUS ACTIVITIES BY MORE THAN ONE ORGANIZATION INDICATE COOPERATIVE EFFORTS.

LEGEND:


- OPERATION
- REVIEW
- ▲ DECISION

- NORMAL FLOW
- - - NON-COMPETITIVE CONTRACTS

\* AD HOC COMMITTEES MAY BE USED — INCLUDES OUTSIDE SCIENTISTS.

# STATE DISTRIBUTION OF GRANTS AND CONTRACTS — FISCAL YEAR 1981


(DOLLARS IN THOUSANDS)



NOTE: Contract figures exclude Foreign Contracts: \$7,226; Grant figures exclude Foreign Grants: \$4,099, Scientific Evaluation (DRG): \$965, and Scientific Evaluation (NCI): \$2,048.

# DISTRIBUTION OF CANCER CONTROL GRANTS AND CONTRACTS — FISCAL YEAR 1981

(DOLLARS IN THOUSANDS)



▲ 120 GRANTS	Total \$25,780
■ 116 CONTRACTS	Total 28,053
<b>Total Obligations</b>	<b>\$53,833</b>

# INSTITUTIONS RECEIVING MORE THAN \$2,000,000 FROM THE NATIONAL CANCER INSTITUTE IN FISCAL YEAR 1981

(DOLLARS IN THOUSANDS)

NAME OF INSTITUTION	GRANTS	CONTRACTS	CONSTRUCTION	TOTAL	LOCATION
Alabama, University of .....	\$ 7,863	\$ 403	\$ —	\$ 8,266	Alabama
American College of Radiology Oncology Study .....	2,448	739	—	3,187	Pennsylvania
American Health Foundation .....	3,893	1,017	—	4,910	New York
Arizona, University of .....	5,938	395	33	6,366	Arizona
Army, Department of, Ft. Detrick .....	127	4,661	—	4,788	Maryland
Arthur D. Little, Inc. ....	—	2,879	—	2,879	Massachusetts
Battelle Memorial Institute .....	—	6,847	—	6,847	Ohio
Baylor College of Medicine .....	5,141	388	—	5,529	Texas
Boston University .....	2,284	36	—	2,320	Massachusetts
California, University of .....	34,778	2,141	—	36,919	California
Case Western Reserve University .....	2,691	75	—	2,766	Ohio
Charles River Breeding Labs .....	—	2,844	—	2,844	Massachusetts
Chicago, University of .....	7,842	295	—	8,137	Illinois
City of Hope National Medical Center .....	2,543	—	—	2,543	California
Cold Spring Harbor Laboratory .....	4,916	5	—	4,921	New York
Colorado, University of .....	3,120	—	—	3,120	Colorado
Columbia University .....	9,886	930	427	11,243	New York
Community Cancer Control (Los Angeles) .....	—	2,023	—	2,023	California
Cornell University .....	3,161	—	—	3,161	New York
Dartmouth College .....	2,982	134	—	3,116	New Hampshire
Duke University .....	8,633	513	—	9,146	North Carolina
Emory University .....	1,319	1,081	—	2,400	Georgia
Energy, Department of .....	—	6,870	—	6,870	Tennessee
Environmental Protection Agency .....	—	2,192	—	2,192	Dist. of Col.
Florida, University of .....	3,044	64	—	3,108	Florida
Fogarty International Center .....	37	11,144	—	11,181	Maryland
Fox Chase Cancer Center .....	1,292	980	—	2,272	Pennsylvania
Franklin Institute Research Labs .....	—	2,594	—	2,594	Pennsylvania
Fred Hutchinson Cancer Research Center .....	10,481	1,636	—	12,117	Washington
Georgetown University .....	2,060	542	—	2,602	Dist. of Col.
Hahnemann Medical College & Hospital of Philadelphia .....	2,186	—	—	2,186	Pennsylvania
Harvard University .....	10,051	50	—	10,101	Massachusetts
Hawaii, University of .....	1,398	2,175	—	3,573	Hawaii
Hazleton Laboratories, Inc. ....	—	3,037	—	3,037	Virginia
IIT Research Institute .....	55	3,061	—	3,116	Illinois
Illinois, University of .....	2,807	291	—	3,098	Illinois
Institute for Cancer Research .....	8,083	83	—	8,166	Pennsylvania
Iowa, University of .....	2,508	2,772	—	5,280	Iowa
IRDC .....	—	3,207	—	3,207	Michigan
Johns Hopkins University .....	13,625	1,438	—	15,063	Maryland
La Jolla Cancer Research Foundation .....	2,030	—	—	2,030	California
Litton Bionetics, Inc. ....	—	30,224	522	30,746	Maryland
Maryland, University of .....	1,742	697	—	2,439	Maryland
Mason Research Institute/EG&G .....	—	5,325	—	5,325	Massachusetts
Massachusetts General Hospital .....	4,818	491	—	5,309	Massachusetts
Massachusetts Institute of Technology .....	8,213	—	—	8,213	Massachusetts
Mayo Foundation .....	4,781	1,865	—	6,646	Minnesota
Meloy Laboratories, Inc. ....	—	2,626	—	2,626	Virginia
Memorial Hospital for Cancer and Allied Diseases .....	4,872	2,222	—	7,094	New York
Miami, University of .....	3,333	443	—	3,776	Florida
Michigan Cancer Foundation .....	2,857	605	—	3,462	Michigan

NAME OF INSTITUTION	GRANTS	CONTRACTS	CONSTRUCTION	TOTAL	LOCATION
Michigan, University of .....	\$ 3,928	\$ -	\$ -	\$ 3,928	Michigan
Microbiological Associates .....	-	3,645	-	3,645	Maryland
Midwest Research Institute .....	115	3,639	-	3,754	Missouri
Minnesota, University of .....	5,580	1,365	-	6,945	Minnesota
Mount Sinai School of Medicine .....	4,775	637	-	5,412	New York
Nebraska, University of .....	2,177	160	-	2,337	Nebraska
New Mexico, University of .....	3,973	898	-	4,871	New Mexico
New York State Department of Health .....	13,483	501	-	13,984	New York
New York University .....	7,425	140	-	7,565	New York
North Carolina, University of .....	4,679	238	-	4,917	North Carolina
Northern California Cancer Program, Inc. ....	2,557	14	-	2,571	California
Northwestern University .....	2,159	48	318	2,525	Illinois
Ohio State University .....	4,294	324	-	4,618	Ohio
ORI, Inc. ....	-	2,286	-	2,286	Maryland
Pennsylvania State University .....	3,537	-	-	3,537	Pennsylvania
Pennsylvania, University of .....	7,331	76	-	7,407	Pennsylvania
Pittsburgh, University of .....	2,058	2,773	-	4,831	Pennsylvania
Rochester, University of .....	7,848	360	317	8,525	New York
Rockefeller University .....	4,203	-	-	4,203	New York
Salk Institute for Biological Studies .....	3,800	127	-	3,927	California
Scripps Clinic and Research Foundation .....	4,440	71	-	4,511	California
Sidney Farber Cancer Institute .....	15,312	199	-	15,511	Massachusetts
Sloan-Kettering Institute for Cancer Research ..	21,673	509	-	22,182	New York
Southern California, University of .....	8,983	1,207	-	10,190	California
Southern Research Institute .....	2,348	3,702	-	6,050	Alabama
SRI International .....	1,243	3,376	-	4,619	California
St. Jude Children's Research Hospital .....	4,502	-	-	4,502	Tennessee
Stanford University .....	8,780	835	-	9,615	California
State University of New York .....	4,342	55	-	4,397	New York
Temple University .....	3,972	218	-	4,190	Pennsylvania
Tennessee, University of .....	1,963	215	-	2,178	Tennessee
Texas, University of .....	23,918	1,649	-	25,567	Texas
Thomas Jefferson University .....	2,441	252	-	2,693	Pennsylvania
Tracor Jitco, Inc. ....	-	17,650	-	17,650	Maryland
Tufts University .....	2,306	-	-	2,306	Massachusetts
University City Science Center .....	-	2,689	-	2,689	Pennsylvania
Utah, University of .....	4,025	679	-	4,704	Utah
Vanderbilt University .....	2,284	224	-	2,508	Tennessee
Vermont, University of .....	2,002	122	-	2,124	Vermont
Virginia Commonwealth University .....	2,336	-	-	2,336	Virginia
Washington University .....	5,125	-	-	5,125	Missouri
Washington, University of .....	3,914	707	558	5,179	Washington
Wellcome Foundation, Ltd. ....	-	2,112	-	2,112	England
Westat, Inc. ....	-	4,342	-	4,342	Maryland
Wisconsin, University of .....	14,133	385	-	14,518	Wisconsin
Wistar Institute of Anatomy and Biology .....	5,897	-	-	5,897	Pennsylvania
Worcester Foundation for Experimental Biology ..	2,015	-	-	2,015	Massachusetts
Yale University .....	12,465	937	-	13,402	Connecticut
Yeshiva University .....	7,793	172	-	7,965	New York

<b>TOTALS</b> .....	<b>\$451,972</b>	<b>\$173,578</b>	<b>\$2,175</b>	<b>\$627,725</b>
<b>PERCENT OF TOTAL AWARDED ABOVE</b> .....	<b>72.0</b>	<b>27.7</b>	<b>0.3</b>	<b>100.0</b>
<b>TOTAL NCI FISCAL YEAR 1981 OBLIGATIONS</b> .....	<b>\$989,338</b>			
<b>PERCENT OF NCI TOTAL OBLIGATIONS</b> .....	<b>45.7</b>	<b>17.5</b>	<b>0.2</b>	<b>63.4</b>



## DISTRIBUTION OF NCI CONTRACTS — FISCAL YEAR 1981

### PROGRAM DISTRIBUTION

PERCENT OF TOTAL NUMBER OF CONTRACTS	NUMBER OF CONTRACTS	NCI PROGRAM AREA	THOUSANDS OF DOLLARS	PERCENT OF TOTAL DOLLARS
9.5	66	Division of Cancer Biology and Diagnosis	\$ 12,316	5.4
32.7	228	Division of Cancer Treatment	68,844	30.0
39.1	273	Division of Cancer Cause and Prevention	112,335	48.9
17.0	119	Division of Resources, Centers, and Community Activities	28,862	12.6
1.7	12	Office of the Director	7,127	3.1
		<b>TOTALS</b>	<b>\$229,484</b>	

Includes Interagency Agreements.      **698**

### INSTITUTIONAL DISTRIBUTION


PERCENT OF TOTAL NUMBER OF CONTRACTS	NUMBER OF CONTRACTS	TYPE OF INSTITUTION	THOUSANDS OF DOLLARS	PERCENT OF TOTAL DOLLARS
26.4	184	Profit-Making	\$106,285	46.3
31.2	218	Academic	35,882	15.6
25.6	179	Non-Profit	48,977	21.3
9.2	22	State and Local Government	5,281	11.6
3.2	31	Foreign	6,542	2.3
4.4				2.9
		<b>TOTALS</b>	<b>\$229,484</b>	

**698**

NOTE: Excludes contracts that are not in direct support of research or control, such as Cancer Communications, Program Planning, and Construction contracts.

# DISTRIBUTION OF NCI RESEARCH GRANTS BY VALUE OF GRANT AWARD — FISCAL YEAR 1981

**TOTAL GRANT DOLLARS**  
**\$484,176,000**  
**3,095 GRANTS**




Excludes Training and Fellowship Awards, Cancer Control Grants, Construction Grants, Clinical Education, and Career Awards. Includes Clinical Trials and CREG Awards.

# DISTRIBUTION OF THE GRANT DOLLAR — FISCAL YEAR 1981

(DOLLARS IN THOUSANDS)

TOTAL GRANT OBLIGATIONS  
\$550,782



# FOREIGN RESEARCH GRANTS AND CONTRACTS — FISCAL YEAR 1981

	NUMBER OF GRANTS	GRANT DOLLARS AWARDED	NUMBER OF CONTRACTS	CONTRACT DOLLARS AWARDED	TOTAL DOLLARS AWARDED	PERCENT OF TOTAL AMOUNT AWARDED
Australia	5	\$ 278,836	1	\$ 33,900	\$ 312,736	2.8
Belgium	1	218,381	2	279,746	498,127	4.4
Canada	17	704,578	3	444,800	1,149,378	10.1
China	—	—	1	180,000	180,000	1.6
Denmark	1	12,700	—	—	12,700	0.1
England	5	435,743	6	3,074,411	3,510,154	31.0
Finland	4	140,608	—	—	140,608	1.2
France	1	25,000	7	1,839,338	1,864,338	16.5
Germany	1	25,000	—	—	25,000	0.2
Ghana	—	—	1	41,000	41,000	0.4
Israel	11	776,124	2	267,391	1,043,515	9.2
Italy	4	156,994	3	426,100	583,094	5.1
Japan	—	—	3	392,000	392,000	3.5
Korea	1	11,848	—	—	11,848	0.1
Netherlands	—	—	1	15,000	15,000	0.1
Norway	—	—	1	20,000	20,000	0.2
Scotland	—	—	1	139,244	139,244	1.2
South Africa	1	41,250	—	—	41,250	0.4
Sweden	9	753,680	1	73,330	827,010	7.3
Switzerland	4	518,172	—	—	518,172	4.6
<b>TOTAL</b>	<b>65</b>	<b>\$4,098,914</b>	<b>33</b>	<b>\$7,226,260</b>	<b>\$11,325,174</b>	<b>100.0</b>

## APPROPRIATIONS OF THE NCI 1938-1982

1938 .....	\$ 400,000																																																			
1939 .....	400,000																																																			
<b>1940 THROUGH 1946 \$3,879,570</b>		}	<b>0.19%</b>																																																	
			<b>\$21,000,470</b>																																																	
1947 .....	1,820,900																																																			
1948 .....	14,500,000																																																			
1949 .....	22,000,000																																																			
<b>1950 THROUGH 1956 \$149,481,750</b>		}	<b>2.52%</b>																																																	
			<b>\$276,315,750</b>																																																	
1957 .....	48,432,000																																																			
1958 .....	56,402,000																																																			
1959 .....	75,268,000																																																			
<b>1960 THROUGH 1966 \$958,954,000</b>		}	<b>12.75%</b>																																																	
			<b>\$1,393,234,000</b>																																																	
1967 .....	175,656,000																																																			
1968 .....	183,356,000																																																			
1969 .....	185,149,500																																																			
1970 .....	190,486,063	}	<b>5.54%</b>																																																	
1971 .....	230,383,000		<b>\$606,018,563</b>																																																	
<table style="width: 100%; border-collapse: collapse;"> <tbody> <tr> <td rowspan="10" style="font-size: 4em; vertical-align: middle; padding-right: 10px;">}</td> <td style="width: 15%;">1972 .....</td> <td style="width: 15%;">\$ 378,794,000</td> <td style="width: 40%;"></td> <td style="width: 30%;"></td> </tr> <tr> <td>1973 .....</td> <td>492,205,000</td> <td></td> <td></td> </tr> <tr> <td>1974 .....</td> <td>551,191,500</td> <td></td> <td></td> </tr> <tr> <td>1975 .....</td> <td>691,666,000</td> <td></td> <td></td> </tr> <tr> <td>1976 .....</td> <td>761,727,000<sup>1</sup></td> <td></td> <td></td> </tr> <tr> <td>"TQ" .....</td> <td>152,901,000<sup>2</sup></td> <td></td> <td></td> </tr> <tr> <td>1977 .....</td> <td>815,000,000</td> <td></td> <td></td> </tr> <tr> <td>1978 .....</td> <td>872,388,000</td> <td></td> <td></td> </tr> <tr> <td>1979 .....</td> <td>937,129,000<sup>3</sup></td> <td></td> <td></td> </tr> <tr> <td>1980 .....</td> <td>1,000,000,000<sup>4</sup></td> <td></td> <td></td> </tr> <tr> <td>1981 .....</td> <td>989,355,000<sup>5</sup></td> <td></td> <td></td> </tr> <tr> <td>1982 .....</td> <td>986,617,000<sup>6</sup></td> <td></td> <td></td> </tr> </tbody> </table>				}	1972 .....	\$ 378,794,000			1973 .....	492,205,000			1974 .....	551,191,500			1975 .....	691,666,000			1976 .....	761,727,000 <sup>1</sup>			"TQ" .....	152,901,000 <sup>2</sup>			1977 .....	815,000,000			1978 .....	872,388,000			1979 .....	937,129,000 <sup>3</sup>			1980 .....	1,000,000,000 <sup>4</sup>			1981 .....	989,355,000 <sup>5</sup>			1982 .....	986,617,000 <sup>6</sup>		
}	1972 .....	\$ 378,794,000																																																		
	1973 .....	492,205,000																																																		
	1974 .....	551,191,500																																																		
	1975 .....	691,666,000																																																		
	1976 .....	761,727,000 <sup>1</sup>																																																		
	"TQ" .....	152,901,000 <sup>2</sup>																																																		
	1977 .....	815,000,000																																																		
	1978 .....	872,388,000																																																		
	1979 .....	937,129,000 <sup>3</sup>																																																		
	1980 .....	1,000,000,000 <sup>4</sup>																																																		
1981 .....	989,355,000 <sup>5</sup>																																																			
1982 .....	986,617,000 <sup>6</sup>																																																			
<b>78.97%</b>																																																				
<b>\$8,628,973,500</b>																																																				

TOTAL (1938 through 1982) ..... \$10,925,542,283

**TRANSITION QUARTER ("TQ")**—July 1, 1976 through September 30, 1976—The Interim Period in the changing of the Federal Fiscal Year from July 1 through June 30, to October 1 through September 30.

<sup>1</sup> Includes \$18,163,000 for training funds provided by Continuing Resolution.

<sup>2</sup> Includes \$3,201,000 for training funds provided by Continuing Resolution.

<sup>3</sup> Includes \$20,129,000 for training funds provided by Continuing Resolution.

<sup>4</sup> 1980 appropriation authorized under a Continuing Resolution.

<sup>5</sup> Reflects 1981 rescission of \$11,975,000.


<sup>6</sup> Amount included in Continuing Resolution through March 31, 1982.

# COMPARISON OF DOLLARS, POSITIONS AND SPACE

FISCAL YEAR	DOLLARS			POSITIONS			SPACE		
	OBLIGATIONS (\$000's)	PERCENT OF INCREASE OVER BASE YEAR	PERCENT OF INCREASE OVER PRIOR YEAR	ACTUAL FULL-TIME PERMANENT EMPLOYEES	PERCENT OF INCREASE OVER BASE YEAR	PERCENT OF INCREASE OVER PRIOR YEAR	ALLOCATED SPACE (SQUARE FEET)*	PERCENT OF INCREASE OVER BASE YEAR	PERCENT OF INCREASE OVER PRIOR YEAR
1971	232,855	Base Year	—	1426	Base Year	—	321,230	Base Year	—
1972	378,636	62.6	62.6	1665	16.8	16.8	329,587	2.6	2.6
1973	431,245	85.2	13.9	1736	21.7	4.3	357,972	11.4	8.6
1974	581,149	149.6	34.8	1805	26.6	4.0	381,436	18.7	6.6
1975	699,320	200.3	20.3	1849	29.7	2.4	382,485	19.1	0.2
1976	760,751	226.7	8.8	1955	37.1	5.7	387,324	20.6	1.3
1977	814,957	250.0	7.1	1986	39.3	1.6	428,285	33.3	10.6
1978	872,369	275.0	7.2	1969	38.1	-0.9	491,725	53.1	14.8
1979	936,696	302.3	7.4	1973	38.4	0.2	493,156	53.5	0.3
1980	998,047	328.6	6.5	1837	28.8	-6.7	467,730	45.6	-5.2
1981	989,338	324.9	-0.9	1815	27.3	-1.2	472,633	47.1	1.0

\*Does not include field station-assigned space.


# NATIONAL CANCER INSTITUTE OBLIGATIONS AND OUTLAYS



**OBLIGATIONS:** Orders placed, grants and contracts awarded, salaries earned and similar financial transactions which legally utilize or reserve an appropriation for expenditure.

**OUTLAYS:** Payments (cash or checks) made from current or prior year appropriations.

## NCI GRANT AWARDS — 1972-1981



\*Includes Clinical Education and Research Career Program.



# NCI TOTAL RESEARCH PROJECTS — 1976-1981<sup>1</sup>

(DOLLARS IN THOUSANDS)

FISCAL YEAR	TYPE AWARD	REQUESTED		RECOMMENDED		AWARDED		PERCENT FUNDED <sup>3</sup>
		NUMBER	AMOUNT	NUMBER	AMOUNT	NUMBER	AMOUNT	
1976 <sup>2</sup>	Competing							
	New .....	1,681	\$168,582	1,013	\$ 68,791	475	\$ 37,058	46.9
	Renewals .....	460	85,612	363	49,914	256	41,147	70.5
	Board Supplement .....	69	4,557	45	2,121	37	1,846	82.2
	Total .....	2,210	\$258,751	1,421	\$120,826	768	\$ 80,051	54.0
	<b>Noncompeting</b> .....					<b>1,766</b>	<b>\$184,944</b>	
1977	Competing							
	New .....	1,942	\$205,169	1,146	\$ 78,484	396	\$ 30,591	34.6
	Renewals .....	657	102,681	525	58,264	247	33,823	47.0
	Board Supplement .....	60	3,309	38	1,029	16	366	42.1
	Total .....	2,659	\$311,159	1,709	\$137,777	659	\$ 64,780	38.6
	<b>Noncompeting</b> .....					<b>1,474</b>	<b>\$159,692</b>	
1978	Competing							
	New .....	1,936	\$197,460	1,310	\$ 89,506	522	\$ 41,386	39.8
	Renewals .....	719	122,158	610	68,020	348	45,624	57.0
	Board Supplement .....	50	5,388	31	3,545	24	3,302	77.4
	Total .....	2,705	\$325,006	1,951	\$161,071	894	\$ 90,312	45.8
	<b>Noncompeting</b> .....					<b>1,376</b>	<b>\$160,433</b>	
1979	Competing							
	New .....	1,979	\$202,206	1,436	\$108,264	565	\$ 50,351	39.3
	Renewals .....	613	121,689	556	78,166	314	56,651	56.5
	Board Supplement .....	42	4,313	27	1,501	21	1,033	77.8
	Total .....	2,634	\$328,208	2,019	\$187,931	900	\$108,035	44.6
	<b>Noncompeting</b> .....					<b>1,493</b>	<b>\$177,097</b>	
1980	Competing							
	New .....	1,913	\$219,207	1,403	\$117,167	461	\$ 45,303	32.9
	Renewals .....	593	115,053	550	73,680	293	45,802	53.3
	Board Supplement .....	43	2,619	38	1,492	29	1,261	76.3
	Total .....	2,549	\$336,879	1,991	\$192,339	783	\$ 92,366	39.3
	<b>Noncompeting</b> .....					<b>1,762</b>	<b>\$228,959</b>	
1981	Competing							
	New .....	2,017	\$277,145	1,594	\$156,704	483	\$ 53,004	30.3
	Renewals .....	687	131,355	653	91,034	311	48,122	47.6
	Board Supplement .....	61	3,776	47	1,738	32	940	68.1
	Total .....	2,765	\$412,276	2,294	\$249,476	826	\$102,066	36.0
	<b>Noncompeting</b> .....					<b>1,802</b>	<b>\$253,389</b>	

<sup>1</sup> Includes R01 traditional grants, P01 program projects, R23 new investigator research awards, and CREG/RFA's.

<sup>2</sup> FY 1976 includes transition quarter (total of 15 months).

<sup>3</sup> Percent Funded: Number Awarded ÷ Number Recommended.

NIH Publication No. 82-512  
April 1982

